The world of injectables just opened up a little. Today, the FDA approved Botox, otherwise know as botulinum toxin type A, for the temporary improvement of lateral canathal lines—aka crow’s feet.
“This additional indication will provide people with a new FDA approved treatment option for those seeking a smoother appearance by temporarily minimizing the appearance of crow’s feet at the sides of the eyes,” said Susan Walker, M.D., director of the Division of Dermatology and Dental Products in the FDA’s Center for Drug Evaluation and Research.
Today’s approval makes Botox the first botulinum toxin injectable to be given the okay by the FDA to treat crow’s feet. Botox was first approved to treat frown lines in 2002 and has since been given approval to treat problems ranging from an overactive bladder to migraines.
Treatment for both frown lines and crow’s feet can be given at the same time, with the most common side effect in the two clinical efficacy and safety studies reported as swollen eyes.